loading page

Demographics, Histopathology, and Treatment Outcomes of Squamous Cell Carcinoma of the Prostate
  • +7
  • Michael Larkins,
  • Julian A. Gordon,
  • Vaishnavi Siripurapu,
  • Arjun Bhatt,
  • Melisa Pasli,
  • Kristen Armel,
  • Carol Velez-Martinez,
  • Anastasios Mitsakos,
  • Aidan Burke,
  • M. Sean Peach
Michael Larkins
East Carolina University Brody School of Medicine

Corresponding Author:[email protected]

Author Profile
Julian A. Gordon
East Carolina University Brody School of Medicine
Author Profile
Vaishnavi Siripurapu
East Carolina University Brody School of Medicine
Author Profile
Arjun Bhatt
East Carolina University Brody School of Medicine
Author Profile
Melisa Pasli
East Carolina University Brody School of Medicine
Author Profile
Kristen Armel
East Carolina University Brody School of Medicine
Author Profile
Carol Velez-Martinez
East Carolina University
Author Profile
Anastasios Mitsakos
East Carolina University
Author Profile
Aidan Burke
East Carolina University
Author Profile
M. Sean Peach
East Carolina University
Author Profile

Abstract

Background: Squamous cell carcinoma of the prostate (SCCP) is a neoplasm that comprises fewer than 1% of all primary prostate cancer diagnoses. Given its rarity, there is a paucity of data regarding the treatment of this disease. The limited literature points to the potential of local therapy in conjunction with chemotherapy to improve patient mortality. Methods: Using the National Cancer Initiative’s Surveillance, Epidemiology, and End Results (SEER) database, we conducted a retrospective analysis for patients diagnosed with primary SCCP between 2000 and 2018. We analyzed patient demographics, tumor characteristics, such as histology, and patient outcomes based on treatment modality. We generated Kaplan-Meier five-year overall survival (5y OS) curves for these variables. Results: A total of 66 patients were identified. Five-year overall survival was 18%; median overall survival was 13 months. Patients with Grade II and below disease had an increased 5y OS of 48%, compared to 10% for patients with Grade III and Grade IV disease (p < 0.05). Analysis of the 5y OS based on disease histology revealed patients with papillary SCC had a 5y OS of 50%, compared to 26% for patients with papillary carcinoma, not otherwise specified. Analysis of 5y OS stratified by treatment modality revealed no statistically significant change with any treatment (surgery, radiotherapy, and chemotherapy). Conclusions: The literature on SCCP remains sparse; the rarity of this disease limits analysis. While the investigation undertaken in this paper does not find any change in 5y OS regardless of treatment modality, the variation in 5y OS based on histologic classification of SCCP points to a potential route for the future treatment of this disease.
Submitted to Cancer Reports
28 Jan 2024Review(s) Completed, Editorial Evaluation Pending
07 Feb 2024Editorial Decision: Revise Major
23 Feb 2024Review(s) Completed, Editorial Evaluation Pending
23 Feb 2024Reviewer(s) Assigned
10 Apr 2024Editorial Decision: Revise Minor
22 Apr 2024Review(s) Completed, Editorial Evaluation Pending
22 Apr 2024Reviewer(s) Assigned
18 Jul 2024Editorial Decision: Accept